Omeros (OMER) Free Cash Flow (2010 - 2026)
Omeros (OMER) posted Free Cash Flow of -$14.5 million for Q1 2026, up 63.59% sequentially from -$39.8 million in Q4 2025, and up 59.57% YoY from -$9.1 million in Q1 2025.
Analysis
Omeros (OMER) Free Cash Flow (2010 - 2026) Analysis & Trends
Omeros has reported Free Cash Flow for 17 years, with the latest figure at -$14.5 million in Q1 2026.
- Quarterly Free Cash Flow rose 59.57% year-over-year to -$14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$94.8 million (up 33.72% YoY) and the FY2025 annual result came in at -$116.2 million, up 22.02% from the prior year.
- Free Cash Flow climbed to -$14.5 million in Q1 2026 per OMER's latest filing, from -$39.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $174.5 million in Q1 2023 and troughed at -$46.1 million in Q2 2024.
- A 5-year average of -$17.2 million and a median of -$29.0 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 1248.81% in 2023, then sank 123.97% in 2024.
- Over 5 years, Free Cash Flow stood at -$25.4 million in 2022, then tumbled by 37.6% to -$34.9 million in 2023, then gained by 16.99% to -$29.0 million in 2024, then slumped by 37.36% to -$39.8 million in 2025, then surged by 63.59% to -$14.5 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$14.5 million, -$39.8 million, and -$18.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | 4.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.10 Mn |
| Mar 31, 2026 | -14.51 Mn |
| Dec 31, 2025 | -39.79 Mn |
| Sep 30, 2025 | -18.53 Mn |
| Jun 30, 2025 | -21.95 Mn |
| Mar 31, 2025 | -35.88 Mn |
| Dec 31, 2024 | -29.01 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Jun 30, 2024 | -46.07 Mn |
| Mar 31, 2024 | -41.84 Mn |
| Dec 31, 2023 | -34.94 Mn |
| Sep 30, 2023 | -32.68 Mn |
| Jun 30, 2023 | -32.62 Mn |
| Mar 31, 2023 | 174.54 Mn |
| Dec 31, 2022 | -25.40 Mn |
| Sep 30, 2022 | -26.44 Mn |
| Jun 30, 2022 | -19.47 Mn |
| Mar 31, 2022 | -15.19 Mn |
| Dec 31, 2021 | -18.29 Mn |
| Sep 30, 2021 | -23.76 Mn |